Kuros Biosciences Ltd. Logo

Kuros Biosciences Ltd.

Develops biologic technologies for tissue repair and bone regeneration.

KURN | SW

Overview

Corporate Details

ISIN(s):
CH0325814116
LEI:
5299006U5POB2AVTT709
Country:
Switzerland
Address:
Wagisstraße 25, 8952 Schlieren

Description

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-04-24 07:00
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct M…
English 17.0 KB
2024-04-24 02:00
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct M…
English 14.9 KB
2024-04-17 14:05
Annual General Meeting of Kuros Biosciences approves all resolutions
English 10.3 KB
2024-04-17 02:00
Annual General Meeting of Kuros Biosciences approves all resolutions
English 8.1 KB
2024-03-13 07:00
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total m…
English 58.6 KB
2024-03-13 01:00
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total m…
English 50.6 KB
2024-03-08 07:00
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Co…
English 8.2 KB
2024-03-08 01:00
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Co…
English 6.0 KB
2024-02-01 07:00
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
English 12.7 KB
2024-02-01 01:00
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
English 10.6 KB
2024-01-31 07:00
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Inte…
English 17.3 KB
2024-01-31 01:00
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Inte…
English 15.3 KB
2024-01-04 07:00
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfo…
English 23.0 KB
2024-01-04 01:00
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfo…
English 19.6 KB
2023-12-27 07:00
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Tr…
English 23.5 KB

Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kuros Biosciences Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-05-22 N/A Executive member Buy None 221,100.00 CHF
2024-05-21 N/A Non-Executive member Buy None 46,500.00 CHF
2024-05-16 N/A Non-Executive member Buy None 71,460.00 CHF
2024-05-15 N/A Non-Executive member Sell None 1,698,824.00 CHF
2024-05-15 N/A Executive member Sell None 3,120,216.00 CHF
2024-05-07 N/A Non-Executive member Buy None 48,750.00 CHF
2024-04-29 N/A Executive member Sell None 223.04 CHF
2024-04-26 N/A Executive member Sell None 19,296.00 CHF
2024-04-25 N/A Executive member Sell None 30,645.00 CHF
2023-11-29 N/A Executive member Sell None 9,270.00 CHF

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.